简化衰弱量表预测不适合移植新诊断多发性骨髓瘤患者结局:FIRST试验分析
基于FIRST三期试验中新诊断多发性骨髓瘤患者数据,回顾性采用年龄、查尔森共病指数和ECOG体能状态评分构建简化衰弱量表,替代既往EQ-5D问卷。结果显示衰弱组(49%)无进展生存和总生存均劣于非衰弱组(51%),且衰弱联合ISS分期可改善预后评估,衰弱患者3/4级治疗相关不良事件风险更高。
要点
- 年龄、CCI和ECOG PS构成的简化衰弱量表可预测不适合移植NDMM患者结局。
- 衰弱患者无进展生存和总生存均劣于非衰弱患者。
- 衰弱联合ISS分期可改善预后评估,衰弱患者3/4级不良事件风险更高。
核心结论
- 基于年龄、CCI和ECOG PS的简化衰弱量表可预测不适合移植NDMM患者的临床结局,并支持在FIRST试验中验证的治疗效应。
研究设计与样本
- 回顾性分析大型三期FIRST试验中新诊断多发性骨髓瘤患者,使用年龄、CCI和ECOG PS评分替代EQ-5D问卷进行衰弱分组。
- ECOG PS数据纳入1618例患者,分为衰弱组(49%)和非衰弱组(51%)。
主要发现
- 衰弱患者无进展生存和总生存均劣于非衰弱患者。
- 衰弱联合ISS分期(I/II vs III)可改善预后评估。
- 衰弱患者发生3/4级治疗中出现的不良事件风险更高。
- FIRST试验中观察到的治疗效应按衰弱组及衰弱联合ISS组分析均得到确认。
关键数值与推荐
- 衰弱评估采用年龄、查尔森共病指数(CCI)和ECOG体能状态评分。
- 衰弱组占49%,非衰弱组占51%(n=1618)。
临床怎么用
- 该简化衰弱量表易于重复,可用于不适合移植NDMM患者的衰弱评估和预后分层。
- 衰弱联合ISS分期有助于更精细地评估预后。
- 该量表可能有助于未来在衰弱或非衰弱老年骨髓瘤患者中设计研究。
局限性
- 为回顾性分析,基于FIRST试验数据。
- 使用ECOG PS替代EQ-5D生活质量问卷进行衰弱评分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of treatment. Patients from the large, phase 3 FIRST trial in newly diagnosed multiple myeloma (NDMM) were retrospectively investigated to determine outcomes based on frailty using scores for age, Charlson Comorbidity Index (CCI), and Eastern Cooperative Oncology Group performance status (ECOG PS), instead of the EQ-5D quality-of-life questionnaire, as previously reported. ECOG PS (n = 1618) was investigated in frailty groups: frail (49%) and nonfrail (51%). Frail patients experienced worse progression-free and overall survival vs nonfrail patients. Prognostic assessment was improved when combining frailty and International Staging System stage (I/II vs III). Frail patients had a higher risk of developing grade 3/4 treatment-emergent adverse events. Treatment effects observed in the FIRST trial were confirmed per frailty group and per frailty and ISS group. The use of this ECOG PS-containing frailty scale as a predictive measure of clinical outcomes in patients with transplant-ineligible NDMM is supported by data from the FIRST trial. This score, based on age, CCI, and ECOG PS, can be easily replicated and may help design future myeloma studies in frail or nonfrail elderly patients.
引用
- Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2019. PMID: 31427722. doi:10.1038/s41375-019-0539-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。